Evidence map›Paper›PMID 42085339›Full record

ArticleACS chemical neuroscience2026

In Vivo Characterization of Synthetic Cannabidiol Analogs for Seizure Suppression in Zebrafish.

Haoqian Miao, Ralph Zhang, Lain X Pierce, Ricardo DaLuz, Cole Helsell, Vicky Guan, Chae Joon Lee, Maxfield P Benbow, Matthew N McCarroll, Mark Mascal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Haoqian MiaoDepartment of Chemistry, University of California Davis, Davis 95818, California, United States.
Ralph ZhangDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, California, United States.
Lain X PierceDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, California, United States.
Ricardo DaLuzDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, California, United States.ORCID 0009-0009-2095-1894
Cole HelsellDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, California, United States.
Vicky GuanDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, California, United States.
Chae Joon LeeDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, California, United States.
Maxfield P BenbowDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, California, United States.
Matthew N McCarrollDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, California, United States.ORCID 0000-0001-7080-3210
Mark MascalDepartment of Chemistry, University of California Davis, Davis 95818, California, United States.ORCID 0000-0001-7841-253X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy affects over 70 million people worldwide, nearly 20% of whom experience pharmacoresistant forms, particularly in pediatric populations. Cannabidiol (CBD) shows promise for the treatment of neurological disorders, including refractory epilepsy, but its low potency necessitates high dosing, leading to side effects that include drowsiness, gastric issues, and potential hepatotoxicity. Regulatory barriers, high cost, abuse liability, and the poor sustainability of hemp cultivation are further drawbacks to CBD use. In an effort to circumvent these issues, a series of structurally related, synthetic "pseudocannabinoids" have been evaluated for antiseizure activity. A high-throughput zebrafish model was employed using pentylenetetrazole (PTZ) and strobing light stimuli to induce seizures, with drug efficacy assessed by automated behavioral analysis and whole-brain imaging. Several of the tested analogs significantly suppressed PTZ-induced seizures, with some outperforming CBD. Imaging revealed corresponding reductions in neural hyperactivity. This study highlights both the promise of safer, more effective cannabinoids for seizure mitigation and the potential of phenotypic, target-agnostic zebrafish screening as a powerful tool for drug discovery.

Indexed as

AnticonvulsantsCannabidiolSeizuresAnimalsBrainDisease Models, AnimalPentylenetetrazoleZebrafishAnticonvulsantsCannabidiolPentylenetetrazoleantiepilepticsbehavioral profilingcannabidiolcannabinoidsneuropharmacologywhole brain imagingzebrafish

Identifiers

PMID42085339
PMCPMC13195666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.